IMMray PanCan-d approaches the market
Immunovia | 22/03/2018

Immunovia is preparing to market its IMMray PanCan-d for self-pay patients at high risk of pancreatic cancer (PC) in Q418, after preparatory activities…

Preparing to tackle big markets
Immunovia | 07/12/2017

Immunovia continues to leverage the IMMray technology to additional opportunities with prospective trials in the group of early pancreatic cancer symptoms…

New opportunities in sight as first sales approach
Immunovia | 02/10/2017

Immunovia is on track to start commercialising its PanCan-d test for the early detection of pancreatic cancer in high-risk patients in 2018. To this end,…